The global cell therapy processing market was valued at $1,695 million in 2018, and is projected to reach $12,062 million by 2026, registering a CAGR of 27.80% from 2019 to 2026.
Cell therapy is the administration of living cells to replace a missing cell type or to offer a continuous source of a necessary factor to achieve a truly meaningful therapeutic outcome. There are different forms of cell therapy, ranging from transplantation of cells derived from an individual patient or from another donor. The manufacturing process of cell therapy requires the use of different products such as cell lines and instruments. These cell therapies are used for the treatment of various diseases such as cardiovascular disease and neurological disorders.
Increase in the incidence of cardiovascular diseases, rise in the demand for chimeric antigen receptor (CAR) T cell therapy, increase in the R&D for the advancement in the research associated with cell therapy, increase in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies, and a rise in understanding of the role of stem cells in inducing development of functional lung cells from both embryonic stem cells (ESCs) & induced pluripotent stem (iPS) cells are the key factors that fuel the growth of the cell therapy processing market. Moreover, increase in a number of clinical studies relating to the development of cell therapy processing, a rise in the adoption of regenerative drug, introduction of novel technologies for cell therapy processing, increase in government investments for cell-based research, increase in number of GMP-certified production facilities, large number of oncology-oriented cell-based therapy clinical trials, and a rise in the development of allogeneic cell therapy are other factors that augment the growth of the market. However, high-costs associated with the cell therapies, and bottlenecks experienced by manufacturers during commercialization of cell therapies are expected to hinder the growth of the market.
The cell therapy processing market is segmented into offering type, application, and region. By type, the market is categorized into products, services, and software. The application covered in the segment include cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).
KEY BENEFITS FOR STAKEHOLDERS
KEY MARKET SEGMENTS
By Offering Type
By Application
By Region
LIST OF KEY PLAYERS PROFILED IN THE REPORT
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Cell therapy is the administration of living cells to replace a missing cell type or to offer a continuous source of a necessary factor to achieve a truly meaningful therapeutic outcome. There are different forms of cell therapy, ranging from transplantation of cells derived from an individual patient or from another donor. The manufacturing process of cell therapy requires the use of different products such as cell lines and instruments. These cell therapies are used for the treatment of various diseases such as cardiovascular disease and neurological disorders.
Increase in the incidence of cardiovascular diseases, rise in the demand for chimeric antigen receptor (CAR) T cell therapy, increase in the R&D for the advancement in the research associated with cell therapy, increase in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies, and a rise in understanding of the role of stem cells in inducing development of functional lung cells from both embryonic stem cells (ESCs) & induced pluripotent stem (iPS) cells are the key factors that fuel the growth of the cell therapy processing market. Moreover, increase in a number of clinical studies relating to the development of cell therapy processing, a rise in the adoption of regenerative drug, introduction of novel technologies for cell therapy processing, increase in government investments for cell-based research, increase in number of GMP-certified production facilities, large number of oncology-oriented cell-based therapy clinical trials, and a rise in the development of allogeneic cell therapy are other factors that augment the growth of the market. However, high-costs associated with the cell therapies, and bottlenecks experienced by manufacturers during commercialization of cell therapies are expected to hinder the growth of the market.
The cell therapy processing market is segmented into offering type, application, and region. By type, the market is categorized into products, services, and software. The application covered in the segment include cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Offering Type
- Products
- Services
- Software
By Application
- Cardiovascular Devices
- Bone Repair
- Neurological Disorders
- Skeletal Muscle Repair
- Cancer
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East
- Africa
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Cell Therapies Pty Ltd
- Invitrx Inc.
- Lonza Ltd
- Merck & Co., Inc. (FloDesign Sonics)
- NantWorks, LLC
- Neurogeneration, Inc.
- Novartis AG
- Plasticell Ltd.
- Regeneus Ltd
- StemGenex, Inc.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
- Beckman Coulter, Inc.
- Stemcell Technologies
- MiltenyiBiotec GmbH
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: CELL THERAPY PROCESSING MARKET, BY OFFERING TYPE
CHAPTER 5: GLOBAL CELL THERAPY PROCESSING MARKET, BY APPLICATION
CHAPTER 6: CELL THERAPY PROCESSING MARKET, BY REGION
CHAPTER 7: COMPANY PROFILES
Executive Summary
According to this report titled, 'Cell Therapy Processing Market by Offering Type, and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the cell therapy processing market size was valued at $1,695million in 2018, and is projected to reach $12,062million by 2026, growing at a CAGR of 27.8% from 2019 to 2026.Cell therapy is the transplantation of human cells to replace or repair damaged tissue or cells. With new technologies, innovative products and limitless imagination, many different types of cells may be used as part of a therapy or treatment for a variety of diseases and conditions. Some of the cells that may be used include mesenchymal stem cells, dendritic cells, hematopoietic stem cells, skeletal muscle stem cells, lymphocytes and pancreatic islet cells.
The major factors that boost the growth of the cell therapy processing market are rise in the demand for chimeric antigen receptor (CAR) T cell therapy, increase in the incidence of cardiovascular diseases, rise in the R&D for the advancement in the research associated with cell therapy, rise in underst anding of the role of stem cells in inducing development of functional lung cells from both embryonic stem cells (ESCs) & induced pluripotent stem (iPS) cells, rise in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies, and an increase in a number of clinical studies relating to the development of cell therapy processing. In addition, increase in government investments for cell-based research, a rise in the adoption of regenerative drug, introduction of novel technologies for cell therapy processing, rise in the development of allogeneic cell therapy increase in number of GMP-certified production facilities, rise in the development of allogeneic cell therapy, and large number of oncology-oriented cell-based therapy clinical trials are expected to boost the cell therapy processing market growth during the forecast period. However, high-costs associated with the cell therapies, and bottlenecks experienced by manufacturers during commercialization of cell therapies are expected to hinder the growth of the market.
Based on offering type, the market is categorized into products, services, and software. Presently, products dominates the cell therapy processing market, and is anticipated to continue this trend over the forecast period. The key factors that driving the market growth are rise in the incidence of cardiovascular diseases, increase in demand for cell therapy processing, surge in adoption of allogeneic cell therapy, and introduction of novel technologies for cell therapy processing drives the market growth of this segment.
Based on application, the market is classified into cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others. At present, the skeletal muscle repair accounted for the majority of cell therapy processing market share owing to rise in incidence of skeletal muscle injury, rise in geriatric population, increase in The prevalence of chronic diseases, increase in usage of regenerative medicine, and an increase in adoption of minimally invasive surgeries drives the market growth of this segment.
According to Onkar Sumant, Manager, Healthcare, “The growth of the cell therapy processing market is attributed to increase in the incidence of cardiovascular diseases. Furthermore, rise in the demand for chimeric antigen receptor (CAR) t cell therapy, and an increase in the development of stem cell therapy approaches globe are the other factors that contribute to the growth of the cell therapy processing market.”
KEY FINDINGS OF THE STUDY
- Based on offering type, the products segment held more than 82.32% share in the global market in 2018.
- By application, the skeletal muscle repair segment accounted for the largest market share in 2018, and is expected to remain dominant throughout the forecast period.
- Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 29.0% during the forecast period
North America accounted for approximately one-half of the global cell therapy processing market share in 2018 and is expected to remain dominant throughout the forecast period. This was attributed to increase in the popularity of stem cell research, rise in patient awareness towards stem cell therapies, and well developed healthcare infrastructure. On the other side, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to improvement in healthcare infrastructure, a rise in the number of hospitals equipped with advanced medical facilities, the developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare.
Companies Mentioned
- Cell Therapies Pty Ltd
- Invitrx Inc.
- Lonza Ltd
- Merck & Co. Inc. (FloDesign Sonics)
- NantWorks LLC
- Neurogeneration Inc.
- Novartis AG
- Plasticell Ltd.
- Regeneus Ltd
- StemGenex Inc
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 186 |
| Published | March 2020 |
| Forecast Period | 2018 - 2026 |
| Estimated Market Value ( USD | $ 1695 million |
| Forecasted Market Value ( USD | $ 12062 million |
| Compound Annual Growth Rate | 27.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
